Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
INMD 
InMode Ltd (INMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/04/2025: INMD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -23.25% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.26B USD | Price to earnings Ratio 8.04 | 1Y Target Price 21.33 |
Price to earnings Ratio 8.04 | 1Y Target Price 21.33 | ||
Volume (30-day avg) 909153 | Beta 2.08 | 52 Weeks Range 14.87 - 20.98 | Updated Date 04/1/2025 |
52 Weeks Range 14.87 - 20.98 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.25 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 45.91% | Operating Margin (TTM) 28.48% |
Management Effectiveness
Return on Assets (TTM) 8.53% | Return on Equity (TTM) 24.31% |
Valuation
Trailing PE 8.04 | Forward PE 9.05 | Enterprise Value 645320805 | Price to Sales(TTM) 3.19 |
Enterprise Value 645320805 | Price to Sales(TTM) 3.19 | ||
Enterprise Value to Revenue 1.63 | Enterprise Value to EBITDA 5.7 | Shares Outstanding 69558704 | Shares Floating 59832281 |
Shares Outstanding 69558704 | Shares Floating 59832281 | ||
Percent Insiders 13.95 | Percent Institutions 65.54 |
Analyst Ratings
Rating 3.71 | Target Price 20.83 | Buy 1 | Strong Buy 2 |
Buy 1 | Strong Buy 2 | ||
Hold 4 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
InMode Ltd
Company Overview
History and Background
InMode Ltd. was founded in 2008, focusing on developing, manufacturing, and marketing innovative energy-based medical aesthetic solutions. It has grown through organic development and strategic acquisitions, becoming a key player in the aesthetic device market.
Core Business Areas
- Aesthetic Medical Devices: Develops and markets energy-based platforms for various aesthetic procedures, including body contouring, skin rejuvenation, and hair removal.
- Surgical Medical Devices: Develops and markets energy-based platforms for minimally invasive surgical procedures, including women's health, ENT, and gynecology.
Leadership and Structure
The leadership team includes Moshe Mizrahy (Chairman and CEO). The organizational structure is based on functional departments such as R&D, sales and marketing, operations, and finance.
Top Products and Market Share
Key Offerings
- BodyTite: Minimally invasive body contouring device that uses radiofrequency assisted lipolysis (RFAL) technology. InMode holds a significant market share in the RFAL body contouring market. Competitors include Alma Lasers, Cutera and BTL Aesthetics. InMode generated $178.8 million from Surgical technologies in 2023, a 28% increase over 2022.
- Morpheus8: Fractional radiofrequency microneedling device for skin rejuvenation and tightening. Competitors include Endymed, Candela, and Lutronic. Morpheus8 is a significant revenue driver for InMode.
- Evolve: Hands-free body contouring and muscle toning platform. InMode competes with companies like BTL Aesthetics and Allergan Aesthetics in this market.
Market Dynamics
Industry Overview
The aesthetic medical device industry is experiencing strong growth, driven by increasing consumer demand for non-invasive and minimally invasive cosmetic procedures. Technological advancements and expanding applications are fueling market expansion.
Positioning
InMode Ltd is a key player in the energy-based aesthetic device market, known for its innovative RFAL and fractional RF technologies. Its competitive advantages include proprietary technologies, a comprehensive product portfolio, and a strong brand reputation.
Total Addressable Market (TAM)
The global medical aesthetics market is estimated to reach $25 billion by 2027. InMode is positioned to capture a significant share of this market through its innovative products and expanding market reach.
Upturn SWOT Analysis
Strengths
- Innovative proprietary technologies
- Comprehensive product portfolio
- Strong brand reputation
- High gross margins
- Experienced management team
Weaknesses
- Dependence on a limited number of key products
- Relatively small sales and marketing team compared to larger competitors
- Geographical concentration of sales
Opportunities
- Expanding into new geographic markets
- Developing new applications for existing technologies
- Acquiring complementary technologies or companies
- Increasing adoption of minimally invasive procedures
Threats
- Increasing competition from larger medical device companies
- Technological obsolescence
- Changes in regulatory requirements
- Economic downturns affecting consumer spending on elective procedures
Competitors and Market Share
Key Competitors
- ALGN
- ZTS
- CUTR
Competitive Landscape
InMode's competitive advantage lies in its innovative technologies and comprehensive product portfolio. However, it faces competition from larger medical device companies with greater resources and brand recognition.
Major Acquisitions
None
- Year: 0
- Acquisition Price (USD millions): 0
- Strategic Rationale: N/A
Growth Trajectory and Initiatives
Historical Growth: InMode has experienced rapid revenue growth over the past several years, driven by the increasing adoption of its aesthetic devices.
Future Projections: Analysts project continued revenue growth for InMode, driven by new product launches and geographic expansion. The expected growth rates are around 12-15% annually for the next 3-5 years.
Recent Initiatives: Recent strategic initiatives include expanding the sales force in new markets, launching new products (e.g., EmpowerRF), and increasing investment in R&D.
Summary
InMode is a strong company with innovative products and solid financial performance. Its rapid growth and high margins are impressive. However, its reliance on key products and competition are areas to watch out for. Continued innovation and geographic expansion will be critical for sustained success.
Similar Companies
ALGN
Align Technology Inc
ALGN
Align Technology Inc
CUTR
Cutera Inc
CUTR
Cutera Inc
LULU
Lululemon Athletica Inc.
LULU
Lululemon Athletica Inc.
SYK
Stryker Corporation
SYK
Stryker Corporation
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Investor Presentations
- Analyst Reports
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as financial advice. Investment decisions should be based on individual due diligence and consultation with a qualified financial advisor. Market share data is based on estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About InMode Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2019-08-08 | Co-Founder, CEO & Director Mr. Moshe Mizrahy | ||
Sector Healthcare | Industry Medical Devices | Full time employees 599 | Website https://www.inmodemd.com |
Full time employees 599 | Website https://www.inmodemd.com | ||
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company sells and markets its products in the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxemburg, Italy, Germany, Austria, Japan, Australia, and India through distributors. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokne'am, Israel.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.